Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 1, 2012, Pages 262-266

  Plé, Patrick A ^a   Jung, Frédéric ^a   Ashton, Sue ^a   Hennequin, Laurent ^a   Laine, Romuald ^a   Morgentin, Rémy ^a   Pasquet, Georges ^a   Taylor, Sian ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Inhibitors; PDGF; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; AZD 2932; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT;

ALGORITHMS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG DESIGN; ENZYME INHIBITORS; ETHERS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, CHEMICAL; PHOSPHORYLATION; QUINAZOLINES; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84655167998     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.019     Document Type: Article

References (14)

1. Reviewed in P. Carmeliet Oncology 69 2005 4
2. A. Abramsson, P. Lindblom, and C. Betsholtz J. Clin. Invest. 112 2003 1142
3. S. Song, A.J. Ewald, W. Stallcup, and G. Bergers Nat. Cell Biol. 7 2005 870
4. Reviewed in A. Ostman Cytokine Growth Factor Rev. 15 2004 275
5. Vandetanib has been approved by the FDA for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.
6. Cediranib, a selective VEGFR inhibitor, is in phase II. J. Drevs, P. Siegert, M. Medinger, K. Mross, R. Strecker, U. Zirrgiebel, J. Harder, H. Blum, J. Robertson, J.M. Jürgensmeier, T.A. Puchalski, H. Young, O. Saunders, and C. Unger J. Clin. Oncol. 25 2007 3045
7. AZD0530 (Saracatanib), a Src inhibitor, is in phase II. (a) Logie, A.; Jacobs, V.; Fennell, M.; Hargreaves, J.; Westwood, R.; Haupt, N.; Elvin, P.; Wilkinson, R.; Davies, B.; Green, T.P. 18th EORTC-NCI-AACR. Prague, 2006. Abstract # 617. (b) Tabernero, J. ASCO 2007, Abstract # 3520.
8. A. Mortlock, K.M. Foote, N.M. Heron, and F.H. Jung J. Med. Chem. 50 2007 2213
9. Plé, P.; Jung, F.H. Patent WO 2006040526, Chem. Abs. 2006, 144, 412531.
10. Jung, F.H. Patent WO 2006040522, Chem. Abs. 2006, 144, 412507.
11. Plé, P.; Jung, F.H. Patent WO 2006040520, Chem. Abs. 2006, 144, 412530.
12. Hennequin, L.F.A. Patent WO 2003064413, Chem. Abs. 2003, 139, 307787.
13. A.T. Nielsen J. Heterocycl. Chem. 12 1975 1233
14. Heron, N. M.; Pasquet, G. R.; Mortlock, A. A.; Jung, F. Patent WO 2004094410 Chem. Abs. 2004, 141, 395569.